Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage

  • BMO Capital Markets has raised the price target on Beam Therapeutics Inc BEAM to $61 from $41, with a Market Perform rating unchanged.
  • The model changes include updated collaboration revenues for Verve Therapeutics Inc's VERV VERVE-101 program and the incorporation of the Alpha-1 antitrypsin deficiency (AATD) program, modeled at ~$1 billion peak risk-adjusted sales in 2035E.
  • Related: Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics.
  • BMO says that the key points Beam's thesis continues to rely on:
  • Beam's gene editing platform is differentiated preclinically, with best-in-class potential, but clinical derisking is yet to be established.
  • Penetration of Beam's lead assets in the Sickle Cell Disease (SCD) market may be limited given that key competitors are ~3+ years ahead.
  • Diversified pipeline/partnerships can offer long-term optionality. 
  • Related: BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success.
  • The analyst agrees that Beam's AATD and BEAM-102 programs can ultimately be commercially competitive but believe that the underlying risk due to their early stage of development doesn't allow for a high valuation. 
  • Price Action: BEAM shares are up 5.15% at $60.59 during the market session on the last check Monday
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!